PRT-062

PRT-062 is an intranasal spray formulation of **dexmedetomidine**, a potent and highly selective alpha-2 adrenergic receptor agonist. Developed by Sichuan Puruiter Pharmaceutical, the drug is intended for the acute treatment of agitation associated with schizophrenia or bipolar disorder. By activating alpha-2A receptors in the locus coeruleus of the brain, dexmedetomidine inhibits the release of norepinephrine, leading to a reduction in sympathetic activity and producing a calming, sedative effect without significant respiratory depression. The nasal spray delivery system is designed to provide a rapid-onset, non-invasive alternative to traditional intramuscular injections or sublingual films for managing acute psychiatric agitation in clinical settings.

Other names

PRT-062 nasal sprayPRT062 nasal sprayPRT 062 nasal spraydexmedetomidine nasal spray